Phosphogluconate dehydrogenase is a predictive biomarker for immunotherapy in hepatocellular carcinoma

BACKGROUND: Phosphogluconate dehydrogenase (PGD) is involved in the regulation of various tumors. However, its role in hepatocellular carcinoma (HCC) is poorly understood. This study tried to determine the prognostic efficacy of PGD and its value for immunotherapy in HCC. METHODS: The data from the...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Tiantian, Qi, Jianni, Wu, Hao, Wang, Le, Zhu, Lihui, Qin, Chengyong, Zhang, Jiao, Zhu, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632284/
https://www.ncbi.nlm.nih.gov/pubmed/36338768
http://dx.doi.org/10.3389/fonc.2022.993503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632284/
https://www.ncbi.nlm.nih.gov/pubmed/36338768
http://dx.doi.org/10.3389/fonc.2022.993503

Ejemplares similares